Susquehanna International Group, LLP Prometheus Biosciences, Inc. Transaction History

Susquehanna International Group, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$103.46 - $126.29 $4.53 Million - $5.53 Million	43,823 Added 695.05%	50,128 $5.38 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $1.22 Million - $3.98 Million	-33,956 Reduced 84.34%	6,305 $693,000
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $777,830 - $1.63 Million	27,612 Added 218.29%	40,261 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$22.39 - $38.94 $25,994 - $45,209	1,161 Added 10.11%	12,649 $357,000
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $346,133 - $574,400	11,488 New	11,488 $434,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.